Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863

BRAFE600-associated senescence-like cell cycle arrest of human naevi

Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160

RAS oncogenes: the first 30 years

Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 1×

High frequency of BRAF mutations in nevi

Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730

The RAF proteins take centre stage

Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,223

Targeting the mitogen-activated protein kinase cascade to treat cancer

Sebolt, J. S., & Herrera, R. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1503 · Cited by 1,103

Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis

Sparmann, A., & Bar‐Sagi, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.028 · Cited by 880

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872

BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., GIORGI, V. D., Massi, D., Fonsatti, E., Staibano, S., Nappi, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.2452 · Cited by 488

Intratumor and Intertumor Heterogeneity in Melanoma

Grzywa, T. M., Paskal, W., & Wlodarski, P. K. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.09.007 · Cited by 314

Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types

Fredriksson, N. J., Ny, L., Nilsson, J. A., & Larsson, E. (2014) · Nature Genetics · doi:10.1038/ng.3141 · Cited by 295

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

Yancovitz, M., Litterman, A. J., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Darvishian, F., Christos, P. J., Mazumdar, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029336 · Cited by 287

BRAFE600 in benign and malignant human tumours

Michaloglou, C., Vredeveld, L. C. W., Mooi, W. J., & Peeper, D. S. (2007) · Oncogene · doi:10.1038/sj.onc.1210704 · Cited by 278

Toward a Molecular Classification of Melanoma

Fecher, L. A., Cummings, S. D., Keefe, M. J., & Alani, R. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0442 · Cited by 255

The origins and genetic interactions of KRAS mutations are allele- and tissue-specific

Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208

Oncogenes in Cell Survival and Cell DeathPreprint

Shortt, J., & Johnstone, R. W. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009829 · Cited by 200

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

Unni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S.-Q., & VARMUS, H. E. (2015) · eLife · doi:10.7554/elife.06907 · Cited by 188

Targeting the ERK Signaling Pathway in Melanoma

Savoia, P., Fava, P., Casoni, F., & Cremona, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061483 · Cited by 195

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

Smalley, I., Paraiso, K. H. T., & Smalley, K. S. M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.015 · Cited by 194

Main roads to melanoma

Palmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., & Ascierto, P. A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-86 · Cited by 190

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations

Tsao, S. C., Weiss, J. M., Hudson, C., Christophi, C., Cebon, J. S., Behren, A., & Dobrovic, A. (2015) · Scientific Reports · doi:10.1038/srep11198 · Cited by 173

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

Fedorenko, I. V., Gibney, G. T., & Smalley, K. S. M. (2012) · Oncogene · doi:10.1038/onc.2012.453 · Cited by 180

A brief history of melanoma

Rebecca, V. W., Sondak, V. K., & Smalley, K. S. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328351fa4d · Cited by 176

Mutant V600E BRAF Increases Hypoxia Inducible Factor-1α Expression in Melanoma

Kumar, S., Yu, H., Edwards, R. H., Chen, L., Kazianis, S., Brafford, P. A., Ács, G., Herlyn, M., & Xu, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3312 · Cited by 147

The Primary Occurrence ofBRAFV600EIs a Rare Clonal Event in Papillary Thyroid Carcinoma

Guerra, A., Sapio, M. R., Marotta, V., Campanile, E., Rossi, S., Forno, I., Fugazzola, L., Budillon, A., Moccia, T., Fenzi, G., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0618 · Cited by 140

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma

Costa, Â. M., Herrero, A., Fresno, M., Heymann, J. J., Alvarez, J. A., Cameselle‐Teijeiro, J., & García‐Rostán, G. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03077.x · Cited by 129

Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags

Wee, E. J. H., Wang, Y., Tsao, S., & Trau, M. (2016) · Theranostics · doi:10.7150/thno.15871 · Cited by 113

Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells

Unni, A. M., Harbourne, B., Oh, M. H., Wild, S. A., Ferrarone, J. R., Lockwood, W. W., & VARMUS, H. E. (2018) · eLife · doi:10.7554/elife.33718 · Cited by 111

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF

Cisowski, J., Sayin, V. I., Liu, M., Karlsson, C., & Bergo, M. O. (2016) · Oncogene · doi:10.1038/onc.2015.186 · Cited by 104

Cancer driver mutations in protein kinase genes

Torkamani, A., Verkhivker, G. M., & Schork, N. J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.11.008 · Cited by 102

Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets

Palmieri, G., Ombra, M. N., Colombino, M., Casula, M., Sini, M. C., Manca, A., Paliogiannis, P., Ascierto, P. A., & Cossu, A. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00183 · Cited by 110

Acquired Secondary RAS Mutation in BRAF V600E -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors

Cabanillas, M. E., Dadu, R., Iyer, P., Wanland, K. B., Busaidy, N. L., Ying, A. K., Gule-Monroe, M. K., Wang, J. R., Zafereo, M., & Hofmann, M.-C. C. (2020) · Thyroid · doi:10.1089/thy.2019.0514 · Cited by 103

Signaling from the Human Melanocortin 1 Receptor to ERK1 and ERK2 Mitogen-Activated Protein Kinases Involves Transactivation of cKIT

Herráiz, C., Journé, F., ABDEL‐MALEK, Z. A., Ghanem, G., Jiménez‐Cervantes, C., & García-Borrón, J. C. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0217 · Cited by 107

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma

Shah, D., & Dronca, R. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.02.002 · Cited by 100

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes

El-Osta, H. E., Falchook, G. S., Tsimberidou, A. M., Hong, D. S., Naing, A., Kim, K., Wen, S., Jankú, F., & Kurzrock, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025806 · Cited by 94

Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities

Eddy, K., Shah, R., & Chen, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626129 · Cited by 104

Intratumoral Heterogeneity as a Therapy Resistance Mechanism

Somasundaram, R., Villanueva, J., & Herlyn, M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00011-7 · Cited by 91

miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma

Felli, N., Felicetti, F., Lustri, A. M., Errico, M. C., Bottero, L., Cannistraci, A., Feo, A. D., Petrini, M., Pedini, F., Biffoni, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056824 · Cited by 93

Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity

Petti, C., Molla, A., Vegetti, C., Ferrone, S., Anichini, A., & Sensi, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4671 · Cited by 92

Phytochemicals for the Management of Melanoma

Pal, H. C., Hunt, K. M., Diamond, A. C., Elmets, C. A., & Afaq, F. (2016) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557516666160211120157 · Cited by 89

Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance

Raaijmakers, M. I. G., Widmer, D. S., Narechania, A., Eichhoff, O. M., Freiberger, S. N., Wenzina, J., Cheng, P. F., Mihic‐Probst, D., DeSalle, R., Dummer, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12848 · Cited by 82

Induction of Autophagy and Inhibition of Melanoma Growth In Vitro and In Vivo by Hyperactivation of Oncogenic BRAF

Maddodi, N., Huang, W., Havighurst, T., Kim, K., Jack Longley, B., & Setaluri, V. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.26 · Cited by 80

Sequence and Structure Signatures of Cancer Mutation Hotspots in Protein Kinases

Dixit, A., Yi, L., Gowthaman, R., Torkamani, A., Schork, N. J., & Verkhivker, G. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007485 · Cited by 83

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells

Loria, R., Bon, G., Perotti, V., Gallo, E., Bersani, I., Baldassari, P., Porru, M., Leonetti, C., Carlo, S. E. D., Visca, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2995 · Cited by 80

BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy

Colombino, M., Sperlongano, P., Izzo, F., Tatangelo, F., Botti, G., Lombardi, A., Accardo, M., Tarantino, L., Sordelli, I., Agresti, M., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2011.136 · Cited by 81

Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions

Einarsdottir, B. O., Bagge, R. O., Bhadury, J., Jespersen, H., Mattsson, J., Nilsson, L. M., Truvé, K., López, M. D., Naredi, P. L. J., Nilsson, O., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2445 · Cited by 78

Mutation analysis of the EGFR–NRAS–BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma

Akslen, L. A., Puntervoll, H. E., Bachmann, I. M., Straume, O., Vuhahula, E. A. M., Kumar, R., & Molven, A. (2008) · Melanoma Research · doi:10.1097/cmr.0b013e3282f32517 · Cited by 78

DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations

Marzese, D. M., Scolyer, R. A., Roqué, M., Vargas-Roig, L. M., Huynh, J. L., Wilmott, J. S., Murali, R., Buckland, M. E., Barkhoudarian, G., Thompson, J. F., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou107 · Cited by 73

Heterogeneity in Melanoma

Shannan, B., Perego, M., Somasundaram, R., & Herlyn, M. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_1 · Cited by 70

Does the gene matter? Genotype–phenotype and genotype–outcome associations in congenital melanocytic naevi

Polubothu, S., McGuire, N., Al-Olabi, L., Baird, W., Bulstrode, N., Chalker, J., Josifova, D. J., Lomas, D., O’Hara, J., Ong, J., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18106 · Cited by 73

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 72

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape

Vanni, I., Tanda, E. T., Spagnolo, F., Andreotti, V., Bruno, W., & Ghiorzo, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00113 · Cited by 69

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

Hammerlindl, H., & Schaider, H. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0435-1 · Cited by 70

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

Lelliott, E. J., McArthur, G. A., Oliaro, J., & Sheppard, K. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661737 · Cited by 65

Concomitant BRAF V600E Mutation and RET/PTC Rearrangement Is a Frequent Occurrence in Papillary Thyroid Carcinoma

Guerra, A., Zeppa, P., Bifulco, M., & Vitale, M. (2013) · Thyroid · doi:10.1089/thy.2013.0235 · Cited by 64

Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability

Deng, Y., Luo, S., Deng, C., Luo, T., Yin, W., Zhang, H., Zhang, Y., Zhang, X., Lan, Y., Ping, Y., et al. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx109 · Cited by 65

Modeling Evolutionary Dynamics of Epigenetic Mutations in Hierarchically Organized Tumors

Sottoriva, A., Vermeulen, L., & Tavaré, S. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001132 · Cited by 65

Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance

Fugazzola, L., Muzza, M., Pogliaghi, G., & Vitale, M. (2020) · Cancers · doi:10.3390/cancers12020383 · Cited by 62

Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation

Schwartz, A. L., Nath, P. R., Allgäuer, M., Lessey-Morillon, E. C., Sipes, J. M., Ridnour, L. A., Morillon, Y. M., Yu, Z., Restifo, N. P., & Roberts, D. D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02397-7 · Cited by 61

Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

Vecchio, M. D., Mortarini, R., Canova, S., Guardo, L. D., Pimpinelli, N., Sertoli, M. R., Bedognetti, D., Queirolo, P., Morosini, P., Perrone, T., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2363 · Cited by 60

Metastatic pathways in patients with cutaneous melanoma

Adler, N. R., Haydon, A. M., McLean, C., Kelly, J. W., & Mar, V. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12544 · Cited by 64

Understanding spitzoid tumours: new insights from molecular pathology

Forno, P. D., Fletcher, A. A., Pringle, J. H., & Saldanha, G. S. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08207.x · Cited by 58

Heterogeneity in Melanoma

Ng, M. F., Simmons, J. L., & Boyle, G. M. (2022) · Cancers · doi:10.3390/cancers14123030 · Cited by 60

Frequent intra-tumoural heterogeneity of promoter hypermethylation in malignant melanoma.

Rastetter, M., Schagdarsurengin, U., Lahtz, C., Fiedler, E., Marsch, W. C., Dammann, R., & Helmbold, P. (2007) · PubMed · doi:10.14670/hh-22.1005 · Cited by 55

KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations

Liu, X., Zhang, S., McGeary, M. K., Krykbaeva, I., Lai, L., Jansen, D. J., Kales, S. C., Simeonov, A. M., Hall, M. D., Kelly, D. P., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0395 · Cited by 52

Progress in melanoma modelling in vitro

Marconi, A., Quadri, M., Saltari, A., & Pincelli, C. (2018) · Experimental Dermatology · doi:10.1111/exd.13670 · Cited by 51

Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling

Tripathi, R. P., Liu, Z., Jain, A., Lyon, A., Meeks, C., Richards, D., Liu, J., He, D., Wang, C., Nespi, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19075-3 · Cited by 51

Non-Redundancy within the RAS Oncogene Family: Insights into Mutational Disparities in Cancer

Lau, K. S., & Haigis, K. M. (2009) · Molecules and Cells · doi:10.1007/s10059-009-0143-7 · Cited by 55

The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases

Eloy, C., Santos, J., Soares, P., & Sobrinho-Simões, M. A. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1133-7 · Cited by 51

Mutational status of naevus-associated melanomas

Shitara, D. I., Tell‐Martí, G., Bádenas, C., Enokihara, M. M. S. S., Alós, L., Larque, A. B., Michalany, N. S., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13829 · Cited by 50

Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma

Johansson, C. C., Egyházi, S., Masucci, G. V., Harlin, H., Mougiakakos, D., Poschke, I. C., Nilsson, B. R., Garberg, L., Tuominen, R., Lindén, D., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0631-1 · Cited by 49

Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy

Casula, M., Muggiano, A., Cossu, A., Budroni, M., Caracò, C., Ascierto, P. A., Pagani, E., Stanganelli, I., Canzanella, S., Sini, M. C., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-352 · Cited by 49

NFATc2 is an intrinsic regulator of melanoma dedifferentiation

Perotti, V., Baldassari, P., Molla, A., Vegetti, C., Bersani, I., Maurichi, A., Santinami, M., Anichini, A., & Mortarini, R. (2015) · Oncogene · doi:10.1038/onc.2015.355 · Cited by 52

RASandRAFmutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis

Dadzie, O. E., Yang, S., Emley, A., Keady, M., Bhawan, J., & Mahalingam, M. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08887.x · Cited by 45

Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma

Yancovitz, M., Yoon, J., Mikhail, M., Gai, W., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Chapman, P. B., Osman, I., & Polsky, D. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060135 · Cited by 44

NFATc2 Is a Potential Therapeutic Target in Human Melanoma

Perotti, V., Baldassari, P., Bersani, I., Molla, A., Vegetti, C., Tassi, E., Col, J. D., Dolcetti, R., Anichini, A., & Mortarini, R. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.179 · Cited by 43

What makes oncogenes mutually exclusive?

Cisowski, J., & Bergö, M. O. (2016) · Small GTPases · doi:10.1080/21541248.2016.1212689 · Cited by 48

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells

Hmada, Y. A., Brodell, R. T., Kharouf, N., Flanagan, T. W., AlAmodi, A. A., Hassan, S.-Y., Shalaby, H., Hassan, S.-L., Haïkel, Y., Megahed, M., et al. (2024) · Cancers · doi:10.3390/cancers16020470 · Cited by 44

Benign thyroid nodules with RAS mutation grow faster

Puzziello, A., Guerra, A., Murino, A., Izzo, G., Carrano, M., Angrisani, E., Zeppa, P., Marotta, V., Faggiano, A., & Vitale, M. (2015) · Clinical Endocrinology · doi:10.1111/cen.12875 · Cited by 39

Broad spectrum identification of SUMO substrates in melanoma cells

Ganesan, A. K., Kho, Y., Kim, S. C., Chen, Y., Zhao, Y., & White, M. A. (2007) · PROTEOMICS · doi:10.1002/pmic.200600971 · Cited by 37

IER2-induced senescence drives melanoma invasion through osteopontin

Kyjacová, L., Saup, R., Rönsch, K., Wallbaum, S., Dukowic‐Schulze, S., Foss, A., Scherer, S. D., Rothley, M., Neeb, A., Grau, N., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02027-6 · Cited by 38

NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas

Uguen, A., Talagas, M., Costa, S., Samaison, L., Paule, L., Alavi, Z., Braekeleer, M. D., Maréchal, C. L., & Marcorelles, P. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0359-0 · Cited by 36

Biological challenges of BRAF inhibitor therapy

Puzanov, I. J., Burnett, P., & Flaherty, K. T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.005 · Cited by 38

Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers

Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 36

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring

Klinac, D., Gray, E. S., Millward, M. J., & Ziman, M. R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00054 · Cited by 38

The immune‐related role of BRAF in melanoma

Tomei, S., Bedognetti, D., Giorgi, V. D., Sommariva, M., Civini, S., Reinboth, J., Hashmi, M. A., Ascierto, M. L., Liu, Q., Ayotte, B. D., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.014 · Cited by 36

Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay

Bidshahri, R., Attali, D., Fakhfakh, K., McNeil, K., Karsan, A., Won, J., Wolber, R. A., Bryan, J., Hughesman, C. B., & Haynes, C. A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.09.003 · Cited by 35

Targeting ERK beyond the boundaries of the kinase active site in melanoma

Sammons, R. M., Ghose, R., Tsai, K. Y., & Dalby, K. N. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23047 · Cited by 37

Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles

Tringali, C., Silvestri, I., Testa, F., Baldassari, P., Anastasia, L., Mortarini, R., Anichini, A., López‐Requena, A., Tettamanti, G., & Venerando, B. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-560 · Cited by 33

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

Colombino, M., Lissia, A., Capone, M., GIORGI, V. D., Massi, D., Stanganelli, I., Fonsatti, E., Maio, M., Botti, G., Caracò, C., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-202 · Cited by 33

Issues affecting molecular staging in the management of patients with melanoma

Palmieri, G., Casula, M., Sini, M. C., Ascierto, P. A., & Cossu, A. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00091.x · Cited by 32

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma

Tahiri, A., Redalen, K. R., Ree, A. H., de Wijn, R., Risberg, K., Busch, C., Lønning, P. E., Kristensen, V. N., & Geisler, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072692 · Cited by 32

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade

Penna, I., Molla, A., Grazia, G., Cleris, L., Nicolini, G., Perrone, F., Picciani, B., Vecchio, M. D., de Braud, F., Mortarini, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6600 · Cited by 30

Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment

Hassan, M. (2015) · World Journal of Experimental Medicine · doi:10.5493/wjem.v5.i4.206 · Cited by 30

Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways

Tassi, E., Zanon, M., Vegetti, C., Molla, A., Bersani, I., Perotti, V., Pennati, M., Zaffaroni, N., Milella, M., Ferrone, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2232 · Cited by 29

BRAF V600E Mutation and Papillary Thyroid Cancer: Chicken or Egg?

Xing, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2201 · Cited by 27

Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity

Kaji, T., Yamasaki, O., Takata, M., Otsuka, M., Hamada, T., Morizane, S., Asagoe, K., Yanai, H., Hirai, Y., Umemura, H., et al. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.10.006 · Cited by 27

Melanoma Metabolism: Cell Survival and Resistance to Therapy

Luís, R., Brito, C., & Pojo, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_11 · Cited by 26

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond

Jung, T., Haist, M., Kuske, M., Grabbe, S., & Bros, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189890 · Cited by 26

Models and mechanisms in malignant melanoma

Benjamin, C. L., Melnikova, V. O., & Ananthaswamy, H. N. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20353 · Cited by 28

BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer

Chen, K.-H., Lin, Y., Liau, J., Tsai, J., Tseng, L., Lin, L., Liang, J., Lin, B., Hung, J., Chang, Y., et al. (2016) · Medical Oncology · doi:10.1007/s12032-016-0756-6 · Cited by 25

T-Type Calcium Channels: A Potential Novel Target in Melanoma

Barceló, C., Sisó, P., Maiques, Ó., de la Rosa, I., Martí, R. M., & Macià, A. (2020) · Cancers · doi:10.3390/cancers12020391 · Cited by 27

Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD)

Bentivegna, S., Zheng, J., Namsaraev, E. A., Carlton, V. E. H., Pavlı́ček, A., Moorhead, M., Siddiqui, F. A., Wang, Z., Lee, L., Ireland, J. S., et al. (2008) · Human Mutation · doi:10.1002/humu.20672 · Cited by 24

TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors

Chang, G. A., Wiggins, J. M., Corless, B. C., Syeda, M. M., Tadepalli, J. S., Blake, S., Fleming, N. H., Darvishian, F., Pavlick, A. C., Berman, R. S., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.01.027 · Cited by 23

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma

Grazia, G., Vegetti, C., Benigni, F., Penna, I., Perotti, V., Tassi, E., Bersani, I., Nicolini, G., Canevari, S., Carlo‐Stella, C., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.410 · Cited by 22

NRAS Mutant Melanoma: An Overview for the Clinician for Melanoma Management

Jenkins, R. W., & Sullivan, R. J. (2016) · Melanoma Management · doi:10.2217/mmt.15.40 · Cited by 24

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells

Bonaldi, E., Gargiuli, C., Cecco, L. D., Micali, A., Rizzetti, M. G., Greco, A., Borrello, M. G., & Minna, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115744 · Cited by 23

Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model

Jandova, J., & Wondrak, G. T. (2022) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.10.007 · Cited by 20

Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A et al.. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364

Sensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., Vegetti, C., Nonaka, D., Mortarini, R., Parmiani, G., et al. (2006) · Cited by 23

Abstract LB-103: Molecular exploitation of oncogenic stress in melanoma management

Kumar, R., Ji, Z., Miao, B., Njauw, C.-N. J., & Tsao, H. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-lb-103

Identification of molecular targets of oncogenic NRAs and BRAF involved in regulation of melanoma cell proliferation

Petti, C. (2007) · Open Research Online (The Open University) · doi:10.21954/ou.ro.0000ea3b

Clinical significance of BRAF/NRAS concurrent mutations in a clinic‐based metastatic melanoma cohort

Regno, L. D., Louveau, B., Battistella, M., Sadoux, A., Baroudjian, B., Delyon, J., Serror, K., Allayous, C., Lebbé, C., Mourah, S., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18641 · Cited by 3

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma

Аксененко, М. Б., Сергеевич, А. А., & Ruksha, T. G. (2019) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2019-3-226-231